David A. Kircher

David A. Kircher

Auto-generated profile, based on publicly available information

David A. Kircher

Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, Utah 84112, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
GPGennie Parkman
Gennie Parkman
TTTursun Turapov
Tursun Turapov
DKDavid A. Kircher
David A. Kircher
WBWilliam J. Burnett
William J. Burnett
CSChristopher Stehn
Christopher Stehn
SHSheri Holmen
Sheri Holmen
Aberrant activation of the PI3K–AKT pathway is common in many cancers, including melanoma, and AKT1, 2 and 3 (AKT1–3) are bona fide oncoprotein kinases with well-validated downstream effectors. However, efforts to pharmacologically inhibit AKT have proven to be largely ineffective. In this study, we observed paradoxical effects following either pharmacologic or genetic inhibition of AKT1–3 in melanoma cells. Although pharmacological inhibition was without effect, genetic silencing of all three AKT paralogs significantly induced melanoma cell death through effects on mTOR. This phenotype was rescued by exogenous AKT1 expression in a kinase-dependent manner. Pharmacological inhibition of PI3K and mTOR with a novel dual inhibitor effectively suppressed melanoma cell proliferation in vitro and inhibited tumor growth in vivo. Furthermore, this single-agent–targeted therapy was well-tolerated in vivo and was effective against MAPK inhibitor–resistant patient-derived melanoma xenografts. These results suggest that inhibition of PI3K and mTOR with this novel dual inhibitor may represent a promising therapeutic strategy in this disease in both the first-line and MAPK inhibitor–resistant setting.

15 August 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
GPGennie Parkman
Gennie Parkman
TTTursun Turapov
Tursun Turapov
DKDavid A. Kircher
David A. Kircher
WBWilliam J. Burnett
William J. Burnett
CSChristopher Stehn
Christopher Stehn
MMMartin McMahon
Martin McMahon
Aberrant activation of the PI3K-AKT pathway is common in melanoma but efforts to drug this pathway have proven largely ineffective in patients. In this study, we observed that pharmacological inhibition of AKT was ineffective whereas genetic silencing of all three AKT paralogs significantly abrogated melanoma cell growth through effects on mTORC signaling. This phenotype could be rescued by overexpression of AKT but was dependent on kinase activity. Interestingly, expression of the serine/threonine kinase SGK1 was increased following genetic suppression of AKT but only expression of activated SGK1 could rescue the lethal effect of AKT knockdown. SGK1 also increases tumor growth and decreases survival in a BRAF V600E -driven mouse model of melanoma. Pharmacological inhibition of SGK and AKT reduced cell proliferation. These results demonstrate that SGK1 can compensate for AKT loss in this context and suggest that dual targeting of SGK1 and AKT may represent a novel therapeutic strategy in this disease. SIGNIFICANCE: Although the AKT1, 2 & 3 genes encode: Bona fide oncoprotein kinases; well-validated downstream effectors of PI3’-lipids and: pleiotropic regulators of numerous aberrant properties of cancer cells, their role in melanoma progression and/or maintenance is poorly understood. Here we explore the effects of genetic or pharmacological inhibitors of AKT1-3 and conclude that combined inhibition of AKT plus the related SGK protein kinases may be required to inhibit melanomagenesis.

4 March 2024
Verified
Other
Open access
PDF file
GPGennie Parkman
Gennie Parkman
TTTursun Turapov
Tursun Turapov
DKDavid A. Kircher
David A. Kircher
WBWilliam J. Burnett
William J. Burnett
CSChristopher Stehn
Christopher Stehn
SHSheri Holmen
Sheri Holmen
Supplemental Figure 5 shows that caspase 3 and 8 inhibition protects melanoma cells from siAKT1-3-mediated apoptosis. A, Cell confluency assay upon treatment with siAKT1-3 versus co-treatment with caspase inhibitors. Co-treatment of A375 and MTG004 cells with Z-VAD-FMK, Z-DEVD-FMK, and Z-IETD-FMK inhibitors protected cells against siAKT1-3-mediated cell death. B, Incuycte® Cytotox Red assay comparing siCtrl, siAKT1-3, siCtrl + each caspase inhibitor, and siAKT1-3 + caspase inhibitors. C, Incuycte® Caspase 3/7 assay comparing siCtrl, siAKT1-3, siCtrl + each caspase inhibitor, and siAKT1-3 + caspase inhibitors. The percentage of dead cells stained with Cytotox red and caspase 3/7 reagents increased only in the siAKT1-3 group, indicating complete rescue with caspase 3, 8, or pan inhibition.

4 March 2024
Verified
Other
Open access
PDF file
GPGennie Parkman
Gennie Parkman
TTTursun Turapov
Tursun Turapov
DKDavid A. Kircher
David A. Kircher
WBWilliam J. Burnett
William J. Burnett
CSChristopher Stehn
Christopher Stehn
SHSheri Holmen
Sheri Holmen
Supplementary Figure S7 shows chemical structures of all pharmacological agents utilized in study, including MK2206, GSK2141795, GDC-0941, BYL719, RapaLink-1, GSK650394, GDC-0068, GDC-0084, and INY-03-041.

21 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
KSKarly Stanley
Karly Stanley
MFMiKaela N. Field
MiKaela N. Field
APAdriene M. Pavek
Adriene M. Pavek
AMA. Paulina Medellin
A. Paulina Medellin
SPSavannah N. Pettey
Savannah N. Pettey
SHSheri Holmen
Sheri Holmen
Despite the availability of several FDA-approved therapies, metastatic melanoma remains a significant clinical challenge, particularly for patients with brain metastases, which frequently represent the site of treatment failure and a major cause of melanoma-related mortality. Melanoma exhibits a strong propensity to metastasize to the brain, yet the molecular mechanisms driving this lethal progression remain incompletely understood, limiting the development of effective treatment options. Building on our prior discovery that focal adhesion kinase (FAK) is a key mediator of AKT1-driven brain metastasis, we sought to validate the role of FAK in melanoma progression and metastatic dissemination. Using complementary autochthonous and syngeneic mouse models of BRAF-mutant melanoma, we evaluated the impact of FAK expression on overall survival, primary tumor growth, and metastasis. Through the generation of targeted FAK mutants, we distinguished kinase-dependent from kinase-independent functions and demonstrate that FAK promotes melanoma metastasis in a kinase-dependent manner. Furthermore, we establish that FAK functions downstream of PTEN to drive metastatic progression. Collectively, these findings support the therapeutic potential of FAK inhibition, either alone or in combination with existing treatments, to more effectively combat metastatic melanoma and inform the development of emerging FAK-targeted therapies.

4 March 2024
Verified
Other
Open access
PDF file
GPGennie Parkman
Gennie Parkman
TTTursun Turapov
Tursun Turapov
DKDavid A. Kircher
David A. Kircher
WBWilliam J. Burnett
William J. Burnett
CSChristopher Stehn
Christopher Stehn
SHSheri Holmen
Sheri Holmen
Supplementary Figure S4 demonstrates that siAKT1-3 is specific for human AKT. A, The cell confluency assay of YUMM1.1 mouse melanoma cells under genetic inhibition demonstrated no effect on cell death with siAKT1, siAKT2, siAKT3, or any combination. Error bars indicate standard error of the mean of triplicate wells. B, Immunoblotting of YUMM1.1 cells treated with siCtrl vs siAKT1-3. No knockdown of P-AKT (Ser473) or P-PRAS40 (T246) indicated the specificity of the siRNAs for human AKT.